Abstract: The main object of the present invention relates to the design of magnetic coils. In particular, it is aimed at improving the design of magnetic coils to reach high and very fast magnetic fields. The present invention improves the design of one of the main components, gradient coils system, of imaging equipment based on the technique of magnetic resonance imaging (MRI). In this invention, a magnetic coil with incomplete geometrical configuration is provided. The magnetic coil is characterized in that at least one of its spirals is incomplete. The manufacturing method is based on combinatorial filling. In addition, the magnetic coil presented in this invention can achieve intense and fast magnetic gradients.

Abstract: The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.

Abstract: The invention features a method of screening for drug-drug interactions using combinational arrays. The method includes the steps of: (a) receiving a test drug from a client; (b) contacting the test drug and at least 200 library drugs from a drug library in an assay under conditions that ensure that each test drug/library drug contacting is segregated from the others; (c) recording the result of the contacting step (b); (d) identifying combinations of drugs that produce a result in the assay that is different from the results produced by either drug of the combination by itself, wherein each identified combination indicates an interaction between the test drug and the library drug of the combination; and (e) communicating the results of the identifying step (d) to the client.

Abstract: The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

Abstract: The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

Abstract: Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring drug combination or a composition that comprises an anti-scarring drug combination to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

Abstract: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

Abstract: Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent or a composition that comprises an anti-scarring agent to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

Abstract: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and a Group A enhancer (e.g., antifungal agent, antigout agent, anti-infective agent, antiprotozoal agent, antiviral agent, humectant, sunscreen, vitamin D compound, microtubuline inhibitor, or zinc salt) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and Group A enhancer or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.

Abstract: The invention features methods, kits, and compositions for the treatment of ophthalmic disorders. The compositions include a corticosteroid in combination with a non-steroidal immunophilin-dependent immunosuppressant.

Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient a composition that includes a phenothiazine and another active agent, where predetermined plasma drug levels are achieved and maintained for 12 hours or more.

Abstract: The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.

Abstract: The invention features a method of screening for drug-drug interactions using combinational arrays. The method includes the steps of: (a) providing (i) a test drug; (ii) a drug library; and (iii) an assay, (b) contacting the test drug and at least some of the library drugs from the drug library in the assay under conditions that ensure that each test drug/library drug contacting is segregated from the others, (c) recording the result of the contacting of the test drug and the library drug in the assay, and (d) identifying combinations of drugs that produce a result in the assay that is different from the results produced by either drug of the combination by itself. According to the method, each of the identified combinations indicates an interaction between the test drug and the library drug.